TIDMMPH
RNS Number : 6448C
Mereo BioPharma Group plc
20 October 2020
Mereo BioPharma Appoints Christine Fox as Chief Financial
Officer and Heidi Petersen as Senior Vice President, Regulatory
Affairs
London and Redwood City, Calif., October 20, 2020 - Mereo
BioPharma Group plc (NASDAQ: MREO, AIM: MPH) ("Mereo" or "the
Company"), a clinical stage biopharmaceutical company focused on
oncology and rare diseases, today announced the appointment of
Christine Fox, CPA, as Chief Financial Officer (CFO) and Heidi
Petersen as Senior Vice President, Regulatory Affairs.
Ms. Fox brings an extensive array of financial experience to
Mereo, including a background in financial operations and
reporting, technical accounting and external audit. She replaces
Interim CFO and current Mereo Board member Mr. Michael Wyzga, who
will continue to serve on Mereo's Board. Ms. Petersen brings more
than 25 years of experience in the biopharmaceutical industry, with
regulatory expertise across a range of therapeutic areas including
immuno-oncology. Ms. Petersen's appointment will be effective
November 2, 2020 and Ms. Fox in January 2021.
Denise Scots-Knight, Chief Executive Officer of Mereo, said:
"Christine and Heidi are seasoned financial and regulatory
executives and we are excited to welcome them to Mereo. The
remainder of 2020 and 2021 will be an important period for Mereo as
we expect multiple milestones across our pipeline, including the
initiation of our Phase 1b/2 combination study with our anti-TIGIT
antibody, etigilimab, in the coming weeks. With the addition of
Christine and Heidi, we believe we have an exceptional senior
management team in place as we continue to execute on our clinical
development and business objectives in preparation for our next
stage of growth."
Christine Fox, CPA, as Chief Financial Officer
Ms. Fox is a Certified Public Accountant (CPA) with over 18
years of experience in financial operations and reporting,
technical accounting and external audit. She has a proven track
record of delivering high-quality financial information under
international accounting standards and experience in the execution
of corporate transactions. Prior to joining Mereo, Ms. Fox served
as Group Financial Controller and Treasurer of Travelport where she
managed a global financial operations team. Prior to joining
Travelport, Ms. Fox served more than 10 years at KPMG in the U.S.
and Switzerland, in positions of increasing responsibility, where
she was primarily focused on large multi-national clients reporting
under U.S. GAAP and IFRS across a wide variety of industries,
including the pharmaceutical industry. Ms. Fox received a B.S. in
accounting from Butler University.
Heidi Petersen as Senior Vice President, Regulatory Affairs
Ms. Petersen is a seasoned regulatory affairs professional with
25 years of experience. Prior to joining Mereo, she served as Vice
President, Regulatory Affairs at Kartos Therapeutics. Prior to
Kartos, Ms. Petersen served as Vice President, Regulatory Affairs
at Immune Design (acquired by Merck in 2019) where she provided
global regulatory strategy on the development of the company's
immuno-oncology programs across all stages of clinical development.
Previously, Ms. Petersen served as Vice President, Regulatory
Affairs and Quality at BN-Immunotherapeutics (fully acquired by
Bavarian Nordic in 2009) where she led global regulatory strategy
for the company's early and late-stage immuno-oncology programs.
Earlier in her career, Ms. Petersen served as an independent
regulatory consultant, and held business development and regulatory
affairs positions with Pharmacyclics (subsequently acquired by
AbbVie). She also held regulatory positions with Chiron Corporation
(subsequently acquired by Novartis) and ALZA corporation
(subsequently acquired by Johnson & Johnson). She received a
master's in public health from Columbia University and a B.S. in
biology from Tulane University.
About Mereo BioPharma
Mereo BioPharma is a biopharmaceutical company focused on the
development and commercialization of innovative therapeutics that
aim to improve outcomes for oncology and rare diseases. Mereo's
lead oncology product candidate, etigilimab (Anti-TIGIT), has
completed a Phase 1a dose escalation clinical trial in patients
with advanced solid tumors and has been evaluated in a Phase 1b
study in combination with nivolumab in select tumor types. Mereo's
rare disease product portfolio consists of setrusumab, which has
completed a Phase 2b dose-ranging study in adults with osteogenesis
imperfecta (OI), as well as alvelestat, which is being investigated
in a Phase 2 proof-of-concept clinical trial in patients with
alpha-1 antitrypsin deficiency (AATD) and in a Phase 1b/2 clinical
trial in COVID-19 respiratory disease.
Additional Information
The person responsible for arranging the release of this
information on behalf of the Company is Charles Sermon, General
Counsel.
Forward-Looking Statements
This Announcement contains "forward-looking statements." All
statements other than statements of historical fact contained in
this Announcement are forward-looking statements within the meaning
of Section 27A of the United States Securities Act of 1933, as
amended and Section 21E of the United States Securities Exchange
Act of 1934, as amended. Forward-looking statements usually relate
to future events and anticipated revenues, earnings, cash flows or
other aspects of our operations or operating results.
Forward-looking statements are often identified by the words
"believe," "expect," "anticipate," "plan," "intend," "foresee,"
"should," "would," "could," "may," "estimate," "outlook" and
similar expressions, including the negative thereof. The absence of
these words, however, does not mean that the statements are not
forward-looking. These forward-looking statements are based on the
Company's current expectations, beliefs and assumptions concerning
future developments and business conditions and their potential
effect on the Company. While management believes that these
forward-looking statements are reasonable as and when made, there
can be no assurance that future developments affecting the Company
will be those that it anticipates.
All of the Company's forward-looking statements involve known
and unknown risks and uncertainties some of which are significant
or beyond its control and involve assumptions that could cause
actual results to differ materially from the Company's historical
experience and its present expectations or projections. These
forward-looking statements are subject to risks and uncertainties,
including, among other things, those described in the Company's
latest Annual Report on Form 20-F, Reports on Form 6-K and other
documents filed from time to time by the Company with the United
States Securities and Exchange Commission. The Company wishes to
caution investors not to place undue reliance on any
forward-looking statements, which speak only as of the date hereof.
The Company undertakes no obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise, except to the extent
required by law.
Mereo BioPharma Contacts:
Mereo +44 (0)333 023 7300
Denise Scots-Knight, Chief Executive Officer
N+1 Singer (Nominated Adviser and Broker to Mereo ) +44 (0)20 7496 3081
Phil Davies
Will Goode
Burns McClellan (US Investor Relations Adviser to Mereo ) + 01 212 213 0006
Lisa Burns
Steve Klass
FTI Consulting (UK Public Relations Adviser to Mereo ) +44 (0)20 3727 1000
Simon Conway
Ciara Martin
Investors investors@ mereo biopharma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAGCBDGBBDDGGG
(END) Dow Jones Newswires
October 20, 2020 07:00 ET (11:00 GMT)
Mereo Biopharma (LSE:MPH)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Mereo Biopharma (LSE:MPH)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024
